| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501238 | ABBVIE INC | Anti-infective agents and uses thereof |
Dec, 2028
(5 years from now) | |
| US8188104 | ABBVIE INC | Anti-infective agents and uses thereof |
May, 2029
(5 years from now) | |
| US8642538 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | |
| US8420596 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(7 years from now) | |
| US8691938 | ABBVIE INC | Anti-viral compounds |
Apr, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(10 months from now) | |
| US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(10 months from now) | |
| US9139536 | ABBVIE INC | Anti-infective agents and uses thereof |
Nov, 2028
(5 years from now) | |
| US9006387 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9044480 | ABBVIE INC | Compositions and methods for treating HCV |
Apr, 2031
(7 years from now) | |
| US8686026 | ABBVIE INC | Solid compositions |
Jun, 2031
(7 years from now) | |
| US8680106 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8685984 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8466159 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8492386 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US10201542 | ABBVIE INC | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(10 years from now) | |
| US9629841 | ABBVIE INC | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(10 years from now) | |
Viekira Pak (Copackaged) is owned by Abbvie Inc.
Viekira Pak (Copackaged) contains Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir.
Viekira Pak (Copackaged) has a total of 17 drug patents out of which 0 drug patents have expired.
Viekira Pak (Copackaged) was authorised for market use on 19 December, 2014.
Viekira Pak (Copackaged) is available in tablet;oral dosage forms.
Viekira Pak (Copackaged) can be used as treatment of hcv infection using dasabuvir, treatment of hcv infection using ombitasvir, treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin, use of dasabuvir to inhibit viral replication for the treatment of hcv infection., treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin., treatment of hcv infection using paritaprevir.
The generics of Viekira Pak (Copackaged) are possible to be released after 18 October, 2033.
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using paritaprevir, ombitasvir, riton...
Dosage: TABLET;ORAL
VIEKIRA PAK (COPACKAGED) family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic